Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.36 |
| ▸ | ATR | Q13535 | 6/20 | 0.35 |
| ▸ | ATRIP | Q8WXE1 | 5/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5133754 | 0.78 | OGA (0.40) | LRRK2PIK3CA | |
| SCHEMBL4903928 | 0.77 | PDE5A (0.46) | KDM4CHDAC1 | |
| SCHEMBL5134689 | 0.70 | RORC (0.35) | HDAC1 | |
| SCHEMBL13069962 | 0.66 | PIK3CA (0.53) | LRRK2PIK3CA | |
| SCHEMBL4903908 | 0.64 | PDE5A (0.45) | PIK3CAHDAC1 | |
| SCHEMBL5134146 | 0.62 | LMNA (0.38) | HDAC1 | |
| SCHEMBL3122462 | 0.62 | PDE5A (0.36) | — | |
| SCHEMBL18765799 | 0.61 | PIK3CA (0.57) | KDM4CLRRK2PIK3CA | |
| SCHEMBL14554006 | 0.61 | SORD (0.51) | PIK3CA | |
| SCHEMBL17916959 | 0.61 | LRRK2 (0.46) | LRRK2PIK3CAATRATRIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008071650-A2 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-06-19 | — | — | WO | claimed |
| WO-2008071650-A2 | NOVEL COMPOUNDS USEFUL FOR THE TREATMENT OF DEGENERATIVE & INFLAMMATORY DISEASES | GALAPAGOS N.V. (BE) | 2008-06-19 | — | — | WO | disclosed |